Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "US-FDA"

254 News Found

Briefs: Marksans Pharma and Alkem
News | June 22, 2022

Briefs: Marksans Pharma and Alkem

The US FDA had conducted an inspection of Alkem Laboratories Limited's manufacturing facility located at St. Louis, USA.


Apollo Hospitals completes a procedure using new technology SENTINEL
Healthcare | June 16, 2022

Apollo Hospitals completes a procedure using new technology SENTINEL

Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.


Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
News | May 30, 2022

Glenmark Pharma reports revenue growth of 5.6% YoY in Q4

Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022


Piramal Pharma Solutions upgrades Pithampur site
News | May 25, 2022

Piramal Pharma Solutions upgrades Pithampur site

New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses


Piramal Pharma Solutions new API plant in Canada goes online
Biotech | May 19, 2022

Piramal Pharma Solutions new API plant in Canada goes online

It is part of the company's CAD $30 million capital investment in the Aurora, Canada site


Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up
News | May 12, 2022

Suven Pharmaceuticals - CDMO core growth intact; formulations to pick up

Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins


Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
News | May 11, 2022

Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII

The unit is an oral manufacturing facility at Jedcherla, Hyderabad


Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
News | May 10, 2022

Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY

The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt


Sun gets 10 observations from USFDA for Halol facility
News | May 10, 2022

Sun gets 10 observations from USFDA for Halol facility

The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days


Gland launches Bortezomib in the US market
Drug Approval | May 04, 2022

Gland launches Bortezomib in the US market

Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma